EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 36 / No 4 (Avril 2020) Med Sci (Paris), 36 4 (2020) 310-312 References
Open Access
Issue
Med Sci (Paris)
Volume 36, Number 4, Avril 2020
Page(s) 310 - 312
Section Le Magazine
DOI https://doi.org/10.1051/medsci/2020052
Published online 01 May 2020
  1. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018 ; 24 : 908–922. [CrossRef] [PubMed] [Google Scholar]
  2. Ciocan D, Voican CS, Wrzosek L, et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis. Aliment Pharmacol Ther 2018 ; 48 : 961–974. [Google Scholar]
  3. Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017 ; 25 : 1054–62 e1055. [Google Scholar]
  4. Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016 ; 65 : 830–839. [CrossRef] [PubMed] [Google Scholar]
  5. Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013 ; 62 : 1787–1794. [CrossRef] [PubMed] [Google Scholar]
  6. Mirzaei MK, Maurice CF. Menage a trois in the human gut: interactions between host, bacteria and phages. Nat Rev Microbiol 2017 ; 15 : 397–408. [CrossRef] [PubMed] [Google Scholar]
  7. Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019 ; 575 : 505–511. [Google Scholar]
  8. Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab 2019 ; 30 : 675–88e677. [CrossRef] [PubMed] [Google Scholar]
  9. Llorente C, Jepsen P, Inamine T, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun 2017 ; 8 : 837. [PubMed] [Google Scholar]
  10. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013 ; 57 : 601–609. [CrossRef] [PubMed] [Google Scholar]
  11. Jordan B.. Cent ans après, le retour de la phagothérapie ?. Med Sci (Paris) 2019 ; 35 : 806–809. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Chaffringeon L, De La Cruz J, Dettling V, et al. Les bactériophages, alliés de l’épithélium intestinal contre les bactéries pathogènes. Med Sci (Paris) 2019 ; 35 : 581–583. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Dufour N, Debarbieux L. La phagothérapie : une arme crédible face à l’antibiorésistance. Med Sci (Paris) 2017 ; 33 : 410–416. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Gilgenkrantz H, Teillaud JL. (coordinateurs). Le microbiote : cet inconnu qui réside en nous. Med Sci (Paris) 2016 ; 32 : 919–1016. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.